Loading clinical trials...
Loading clinical trials...
This Phase 1a, single center, open-label, repeat dose study will evaluate the safety, efficacy, and Pharmacokinetics of ascending doses of OBP-801 in patients with advanced solid tumors.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Oncolys BioPharma Inc
NCT06659341 · Advanced Solid Tumors Harboring KRAS G12C Mutation
NCT07060989 · Advanced Solid Tumors
NCT07288359 · Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors, and more
NCT05533697 · Advanced Solid Tumors
NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, and more
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions